trending Market Intelligence /marketintelligence/en/news-insights/trending/5PP2vReIPYZB59SV_DJ7KA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly agrees to use DexCom glucose monitor in newest insulin pens, pumps

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lilly agrees to use DexCom glucose monitor in newest insulin pens, pumps

Eli Lilly and Co. has agreed to use a continuous glucose monitoring device from DexCom Inc. with the pharmaceutical giant's insulin delivery devices for patients with diabetes.

The nonexclusive deal will see San Diego-based DexCom's glucose monitors used along with Lilly's pen- and pump-based systems under development.

Dexcom's devices measure blood sugar for patients with diabetes to determine the need for insulin. The monitoring system will provide blood sugar data for the patient to either administer their own insulin with Lilly's pen or feed that information into a closed-loop system connected to an insulin pump that automatically injects insulin.

For diabetes in particular, drug and device makers often collaborate to manage the disease, which requires dependable administration of insulin and can be a burden to patients. DexCom, which worked with Indianapolis-based Lilly to co-develop the automated insulin system, received U.S. approval for its newest glucose monitor in 2018.

Financial details of the commercialization agreement were not disclosed in a Dec. 16 press release announcing the deal.